This is an exciting time in the treatment of diabetes. Continuous, subcutaneous insulin infusion and continuous glucose monitoring technologies are making optimal glucose control accessible to ...

Purpose: Pharmacokinetic and safety data related to the use of inhaled insulin for the management of diabetes mellitus are discussed. The various pulmonary insulin delivery systems under ...

Clinical programs for inhaled insulin have received several setbacks of late, with Bagsværd, Denmark-based Novo Nordisk deciding in January to terminate phase 3 trials of its inhaler and ...

Expert Rev Pharmacoeconomics Outcomes Res. 2008;8(1):33-42. Human inhaled insulin powder (HIIP) is a dry-powder inhaled insulin product, in which regular insulin is captured in large porous ...

It took 10 years and US$1bil (RM3.77bil) for MannKind Corp to get its breakthrough inhaled-insulin drug approved by US regulators. Now comes the hard part: getting people with diabetes to use it.

An FDA committee has given an overwhelming recommendation to new inhaled insulin treatment Afrezza. MannKind Corporation has spent years and many millions of dollars in developing the novel ...

Each subject received in randomized fashion a single dose of 10 International Units of insulin through subcutaneous injection (SC) in one period, and 6.5 milligrams of the inhaled insulin ...

MESA, AZ (AZFamily) — Inhaled insulin is now considered “standard of care” for diabetics, according to updated guidelines from the American Diabetes Association. Inhaled insulin works faster ...

The world's largest drug maker, Pfizer has announced that it intends to fast track its inhaled insulin Exubera in India. The world's largest drug maker, Pfizer has announced that it intends to ...

“The availability of insulin to be inhaled through the lungs will provide a new and innovative option for patients with diabetes mellitus,” he added. Afrezza has been evaluated in over 70 ...

“We are excited for Cipla to market the first inhaled insulin treatment option for adults living with diabetes in India and expect to prepare product for export by the end of 2025.” MannKind entered ...